Zaynich™ enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme drug resistant Gram negative pathogens

In yet another US patient at Houston Methodist Hospital, Texas, Zaynich™ turned out to be a saviour by successfully clearing a chronic bile duct infection, facilitating liver transplant leading to her discharge from the hospital. As per the treating doctor, patient failed to respond to >6 weeks of treatment with high end antibiotics available in US such as cefiderocol and eravacycline. Thus, the treating team was left with no other option but to deploy Zidebactam/Cefepime (WCK 5222) under compassionate use. In the US, the compassionate use approvals are provided by FDA in the form of individual patient specific expanded access IND.

The patient, a 73 year old female with bile duct cancer diagnosed in January 2024, had been undergoing chemotherapy and biliary stent placement. However, developed sepsis and liver abscess as well as cholangitis (an inflammation of the bile ducts) caused by extensively drug resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. She received several broad spectrum antibiotics for >6 weeks but continued to have fever and persistent infection markers precluding liver transplant procedure. 15 days of treatment with Zaynich™ helped control infectious processes and cleared the way for the transplant in this patient. The pathogens from this patient, Pseudomonas aeruginosa and Klebsiella pneumoniae, were found to possess some of the most challenging resistance mechanisms such as IMP, NDM, and OXA 48 which were effectively neutralized by β lactam enhancer mechanism of Zaynich™.

Till date, 45 patients have benefitted under compassionate use of Zidebactam/Cefepime who were suffering from range of life threatening Gram negative infections.

Zaynich™, combination of Zidebactam & Cefepime, is Wockhardt's novel proprietary antibiotic, targeted towards multi drug resistant Gram negative infections. It is currently nearing completion of Phase III study which would support its registration/marketing authorization globally. Earlier, multiple Phase I studies including clinical pharmacology studies with zidebactam/cefepime were conducted in US. Zaynich™ (Zidebactam/Cefepime) is also undergoing a clinical study in India for the treatment of carbapenem resistant infections.

Shares of Wockhardt Limited was last trading in BSE at Rs. 1528.10 as compared to the previous close of Rs. 1396.75. The total number of shares traded during the day was 247630 in over 5561 trades.

The stock hit an intraday high of Rs. 1536.40 and intraday low of 1415.00. The net turnover during the day was Rs. 378341033.00.

Source : Equity Bulls

Keywords

Wockhardt INE049B01025 Zaynich ChronicBileDuctInfection LiverTransplant